Medicus Pharma Secures Global License from Pfizer for CD228-Targeting ADC, Valued at Over $1 Billion in Milestones
核心洞察
Medicus Pharma (搜索) entered a co-development and license agreement with Pfizer for CD228V (搜索) (PF-08046031), an early clinical-stage antibody-drug conjugate targeting melanotransferrin (搜索) (CD228 (搜索)).
Medicus paid a $12 million non-refundable upfront fee and owes $15 million on the first anniversary, while Pfizer contributed $2 million in development funding.
Pfizer is eligible for development, regulatory, and sales milestones exceeding $1 billion plus low double-digit tiered royalties on annual net sales.
Medicus Pharma (搜索) Ltd. (NASDAQ:MDCX) has secured an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V (搜索)), an early clinical-stage antibody-drug conjugate (ADC) targeting melanotransferrin (搜索). The co-development and license agreement, signed and effective September 2, 2026, grants Medicus full rights to utilize CD228V for the treatment, prevention, diagnosis, control, and maintenance of all human diseases and disorders.
Melanotransferrin (搜索), also known as CD228 (搜索), is a cell-surface glycoprotein encoded by the MFI2 gene that is found on melanoma (搜索) cells, a type of skin cancer. The ADC represents an early clinical-stage asset with potential across multiple indications.
Financial Terms and Milestone Structure
To obtain the license, Medicus paid a $12 million non-refundable upfront fee to Pfizer and must pay an additional $15 million on the first anniversary of the agreement. To support initial progress, Pfizer delivered a $2 million development funding payment to Medicus, which must be applied solely toward executing the CD228V (搜索) development plan.
Pfizer stands to gain development, regulatory, and sales milestone payments exceeding $1 billion if all target benchmarks across multiple indications are achieved. The pharmaceutical company is also eligible for low double-digit tiered royalties on annual net sales of CD228V (搜索) products throughout the royalty term.
Operational Roles and Licensing Terms
Although Pfizer maintains patent ownership and participates in co-development oversight, Medicus retains sole authority and financial responsibility for manufacturing, regulatory approval, and commercialization efforts. Medicus will control development and commercialization and may grant sublicenses.
Pfizer holds the right to review budgets, receive progress reports, and elect to fund product development following the initiation of the first pivotal trial. Additionally, Pfizer will receive a portion of specified proceeds in events involving sublicensing, strategic transactions, or a change of control at Medicus.
Unless terminated early, the contract remains effective on a product-by-product and country-by-country basis until the applicable royalty terms expire.
Market Context
Medicus Pharma (搜索) shares were down 32.24% to 18 cents at the time of publication on Thursday, according to Benzinga Pro data.